Trending Tickers: $CRML European Lithium Merger, $AMD Meta AI Partnership, $GMAB Cancer Trial

This week, several stocks caught investors’ attention, driven by significant developments and market momentum. Here’s the breakdown of this week’s trending stocks:

Critical Metals ($CRML) European Lithium Merger Becomes Effective

Critical Metals said on October 27 that its proposed acquisition of Australian-listed European Lithium had become legally effective after court approval and the filing of the court orders. The exchange is scheduled to be implemented on November 5. Eligible European Lithium shareholders are set to receive 0.045 newly issued CRML shares for each share they hold, with the new shares expected to begin trading on Nasdaq on November 6. Because payment is in stock, the value received will move with CRML’s share price.

The companies already have close ties: European Lithium is a major CRML shareholder and previously contributed the Wolfsberg lithium project in Austria. The transaction would also bring European Lithium’s remaining 7.5% stake in the Tanbreez rare-earth project in Greenland under CRML, lifting CRML’s ownership from 92.5% to 100%, according to transaction filings. That simplifies ownership but requires issuing new shares to European Lithium securityholders. The legal milestone does not mean the mining projects have begun producing minerals; development progress and the final share issuance remain the more useful measures to watch.

Stock Price Reaction 

$CRML closed Tuesday, October 27, at $8.13, up 27.43% from Monday’s close.

AMD ($AMD) Deepens Its Meta AI Infrastructure Partnership

AMD announced on October 27 that initial Helios rack-scale AI systems had been installed at Meta and were being tested ahead of a broader deployment. AMD said Meta already uses its EPYC processors and Instinct graphics processors in production. Meta also plans to deploy a custom AMD Instinct GPU tailored to its workloads, while the companies are working together on networking, software, and future chips.

This matters to AMD because Meta is building AI infrastructure at scale, and the collaboration spans more than one component of a data center. Still, AMD did not provide a contract value or a timetable for a full Helios rollout, so installed test systems should not be treated as a completed large-scale deployment. AMD also said it would invest $1 billion in Meta’s equity offering. Meta’s offering announcement described investor indications as nonbinding; the planned investment is distinct from Meta’s spending on AMD hardware.

Stock Price Reaction  

$AMD closed Tuesday at $560.26, up 5.45%. The shares gained another 3.24% on Wednesday, closing at $578.44.

Genmab ($GMAB) Reports Positive Phase 3 Head and Neck Cancer Results

Genmab announced on October 28 that its Phase 3 LiGeR-HN1 trial met both primary endpoints at its first interim analysis. The study compared the experimental antibody petosemtamab plus pembrolizumab with pembrolizumab alone as an initial treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer. The combination improved overall survival, with a hazard ratio of 0.50, meaning the observed risk of death over the study period was 50% lower in the combination group. It also improved the measured tumor response rate; Genmab reported an odds ratio of 3.17.

The survival result is especially important because it measures how patients fared, rather than only whether tumors shrank. Genmab reported no new safety signals and plans to discuss the data with regulators. These are topline results from an interim analysis: the full dataset has yet to be presented, and petosemtamab has not been approved for this use. The next questions are how durable the benefit is, what the detailed safety data show, and how regulators assess the application.

Stock Price Reaction  

$GMAB closed Wednesday at $57.29, up 28.25% from Tuesday’s close. 

This article is for informational purposes only and is not investment advice or a solicitation to buy or sell securities. The content is based on publicly available information and reflects the author’s opinions as of the publication date, which may change without notice. All investments carry inherent risks, including the potential loss of principal, and past performance is not indicative of future results. Forward-looking statements, including references to projected revenues, market trends, or business developments, are based on current expectations and assumptions. Actual results may differ due to various factors, including regulatory changes, economic conditions, competitive pressures, and unforeseen market fluctuations. Readers should conduct their own research or consult a financial advisor before making investment decisions. BBAE holds no position in the securities mentioned, nor are they compensated by the companies mentioned.